India's Ranbaxy says it is set to recover from second-half 20005

19 June 2005

Ranbaxy Laboratories Ltd, India's largest pharmaceutical company by turnover, will start recovering from declining profit starting the second half of 2005, predicts the president of the group's pharmaceutical division, Malvinder Mohan Singh.

"As we go through the year, you will see that every consecutive quarter will be better than the previous one. But the growth will really come in the second half of 2005," Mr Singh said in an interview with the Economic Times of India.

The second half will be better than the first, he said, noting that "a lot is dependent on product flow which will pick up...primarily in the west...but what we have to ensure is that we focus on doing the right thing."

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK





Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight